Main Article Content
Background: Glioblastoma Multiforme (GBM) is a grade IV brain tumour with high recurrence rate despite maximum treatment including surgical resection, concurrent chemo-radiotherapy and adjuvant chemotherapy. In recurrent tumours, there is no standard treatment available.
Patients and Methods: This is a retrospective analysis of patients with recurrent GBM who presented to our department in the period between Jan 2017 to Dec 2018 and received re-irradiation after tumour recurrence. Data were collected from patient medical records to assess DFS, OAS and toxicity.
Results: Totally, 33 patients were enrolled. All cases were re-irradiated to a total dose of 30 Gy in 15 fractions. The overall survival and progression-free survival were significantly better in younger patients with good performance status and small tumour size. Only 2 cases (6.1%) developed deterioration of neurological symptoms.
Conclusion: Brain re-irradiation is a feasible and safe treatment option in patients with recurrent GBM.
Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987-996.
Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances. Crit. Rev. Oncol. Hematol. 2006;60:181-193.
Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J. Clin. Oncol. 2006; 24:1273-1280.
Thomas N. Seyfried, Laura Shelton, Gabriel Arismendi-Morillo, Miriam Kalamian, Ahmed Elsakka, Joseph Maroon. Provocative question: Should ketogenic metabolic therapy become the standard of care for glioblastoma? Mukherjee Neurochemical Research. 2019;44:2392–2404.
Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: Radiographic response and improved survival. J. Neurooncol. 2009; 92:185-191.
Mayer R, Sminia P. reirradiation tolerance of human brain. International Journal of Radiation Oncology, Biology, Physics. 2007;70(5):1350-1360.
Sebastian F. Winter, Franziska Loebel, Jay Loeffler, Tracy T. Batchelor, Maria Martinez-Lage, Peter Vajkoczy. Treatment induced brain tissue necrosis: A clinical challenge in neuro-oncology. Dietrich Neuro-Oncology. 2019;21:1118–1130.
Combs SE, Edler L, Rausch R. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol. 2013; 52:147–52.
Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma: An update. Crit Rev Oncol Hematol. 2016; 99:389–408.
Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997;37:393–398.
Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75:156–163.
Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010; 28:3048–3053.
Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, et al. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol. 2011;103: 683–691.